<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755611</url>
  </required_header>
  <id_info>
    <org_study_id>116745</org_study_id>
    <nct_id>NCT01755611</nct_id>
  </id_info>
  <brief_title>Bioequivalence Minocycline Bioequivalence</brief_title>
  <official_title>Bioequivalence Study Between Two Medications for Oral Administration of Minocycline in 100 mg Oral Solids in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the bioavailability of two medications containing 100 mg
      of minocycline in capsules to determine bioequivalence. They are Minocycline (Minocin® is a
      registered trademark of Wyeth Holdings Corporation), and Minocycline (Minopac® is a
      registered trademark of LABORATORIOS DERMATOLOGICOS DARIER, S.A. DE C.V.). Study design is
      randomized, open, cross-over with two single administrations with two periods and two
      sequences with a wash-out period of 7 days between the periods. Subjects in the study will be
      25 healthy male volunteers, 18-55 years, Blood samples will be obtained at 0.0, 0.33, 0.66,
      1.0, 1.33, 1.66, 2.0, 2.33, 2.66, 3.0, 4.0, 6.0, 8.0, 12.0, 16.0, 24.0, 48.0, and 72.0 hours
      after medication administration in each period. Plasma minocycline levels will be determined
      by HPLC method with UV detection with previously validated method. Minocycline concentration
      data will be used to calculate Cmax, AUC0-t, and AUC0-inf with WinNonlin 5.3 software. The
      log transformed pharmacokinetics parameters of test and reference medications will be
      compared calculating ratios and 90% confidence intervals. Any adverse event will be reported.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2011</start_date>
  <completion_date type="Actual">June 25, 2011</completion_date>
  <primary_completion_date type="Actual">June 25, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (CMAX) of drug minocycline</measure>
    <time_frame>0.0, 0.33, 0.66, 1.0, 1.33, 1.66, 2.0, 2.33, 2.66, 3.0, 4.0, 6.0, 8.0, 12.0, 16.0, 24.0, 48.0, and 72.0 hours postdose</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of drug minocycline</measure>
    <time_frame>0.0, 0.33, 0.66, 1.0, 1.33, 1.66, 2.0, 2.33, 2.66, 3.0, 4.0, 6.0, 8.0, 12.0, 16.0, 24.0, 48.0, and 72.0 hours postdose</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Skin Infections (Acne)</condition>
  <arm_group>
    <arm_group_label>A(reference)/B(test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial administration of reference and cross-over to test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(test)/A(reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial administration of test and cross-over to reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline 100mg</intervention_name>
    <description>Test product</description>
    <arm_group_label>B(test)/A(reference)</arm_group_label>
    <arm_group_label>A(reference)/B(test)</arm_group_label>
    <other_name>MINOPAC® is a registered trademark of LABORATORIOS DERMATOLOGICOS DARIER</other_name>
    <other_name>S.A. DE C.V.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline 100mg</intervention_name>
    <description>Reference product</description>
    <arm_group_label>B(test)/A(reference)</arm_group_label>
    <arm_group_label>A(reference)/B(test)</arm_group_label>
    <other_name>MINOCIN® is a registered trademark of Wyeth Holdings Corporation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Males 18-55 years. Healthy based on comprehensive medical history, lab tests, Chest x-ray,
        Electrocardiogram, negative tests for Hepatitis B and C, and HIV. Negative urine doping
        test. BMI 19-26.5 kg/m2. Lab test in normal range +/- 10%. Blood pressure 139-90/89-50,
        heart rate 100-55, respiratory rate 24-17, temperature 37.5-35 °C. Non-smoking at least for
        10 hrs before study. Written informed consent.

        Exclusion Criteria:

        Hypersensitivity to study medication or other related drug. History of cardiovascular,
        renal, hepatic, metabolic, gastrointestinal, neurologic, endocrine, hematopoietic,
        psychiatric or organic condition.

        Requiring any drug interfering with minocycline pharmacokinetics. Exposed to inducers or
        inhibitors of hepatic enzymes. Intake of possible toxic drugs 30 days before study. Intake
        of any drug 14 days or 7 half-lives before study. Hospitalization or severe disease 60 days
        before study. Receiving investigational drug out of study center 30 days before study.
        Blood loss or blood donation ≥ 450 ml 60 days before study. Recent history of drug abuse
        including alcohol. Intake of xanthine containing products 10 hrs before study. Intake of
        grapefruit juice or hot-spice 10 hrs before study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/116745?search=study&amp;search_terms=116745#rs</url>
    <description>Results for study 116745 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minocycline</keyword>
  <keyword>Mexico</keyword>
  <keyword>Acne</keyword>
  <keyword>bioequivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

